TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
Brief Summary: The objective of this study is to demonstrate that the antibacterial activity of TMC207 is better than placebo when added to a standardized Background Regimen (BR) for treatment of multi-drug resistant TB. Also safety and tolerability will be evaluated.


Options:
A: Arm Label: HRZE; Type: ACTIVE_COMPARATOR; Interventions: Drug: isoniazid | Arm Label: MRZE; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) | Intervention Type: DRUG; Name: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol); Assigned to Arm(s): MRZE | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): HRZE
B: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2
C: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis
Brief Summary: To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis


Options:
A: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
B: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
C: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo
D: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis
Brief Summary: To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis


Options:
A: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalazine | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): B
C: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day
D: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis
Brief Summary: To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis


Options:
A: Arm Label: 30 children with UC; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: sterile saline for injection | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MDX-1100 | Intervention Type: BIOLOGICAL; Name: sterile saline for injection; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MDX-1100; Assigned to Arm(s): 1
D: Arm Label: PLC Colon release tablet 1 g; Type: EXPERIMENTAL; Interventions: Drug: Propionyl-L-Carnitine, Drug: Placebo | Arm Label: PLC colon release tablet 2 g; Type: EXPERIMENTAL; Interventions: Drug: Propionyl-L-Carnitine, Drug: Placebo | Arm Label: Placebo PLC colon release tablet 2 g; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propionyl-L-Carnitine; Assigned to Arm(s): PLC Colon release tablet 1 g | Intervention Type: DRUG; Name: Propionyl-L-Carnitine; Assigned to Arm(s): PLC colon release tablet 2 g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC Colon release tablet 1 g, PLC colon release tablet 2 g, Placebo PLC colon release tablet 2 g

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Interactive, Voice Response-Mediated, Follow-up and Triage System for Smoking Cessation in Smokers With Coronary Heart Disease
Brief Summary: A randomized control trial is planned to evaluate an interactive voice response (IVR) mediated follow-up and triage system, against usual care, to help smokers hospitalized with Coronary Heart Disease (CHD) to quit smoking. The investigators hypothesize that compared to usual care, participants in the IVR group will; a) have a significantly higher 7-day point prevalence abstinence rate at 26 and 52 weeks after hospital discharge, b) will have a higher rate of continuous abstinence at 26 and 52 weeks after hospital discharge, c) will use a greater number of proven effective interventions over time, and d) will develop greater self-efficacy with respect to smoking cessation, over time.


Options:
A: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A
B: Arm Label: Directive; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Directive smoking cessation coaching | Arm Label: Nondirective; Type: EXPERIMENTAL; Interventions: Behavioral: Nondirective smoking cessation coaching | Intervention Type: BEHAVIORAL; Name: Nondirective smoking cessation coaching; Assigned to Arm(s): Nondirective | Intervention Type: BEHAVIORAL; Name: Directive smoking cessation coaching; Assigned to Arm(s): Directive
C: Arm Label: Interactive Voice Response Group; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response; Assigned to Arm(s): Interactive Voice Response Group
D: Arm Label: High intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: High intensity disease management, Drug: Bupropion | Arm Label: Low intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Low intensity disease management, Drug: Bupropion | Arm Label: Comparison group; Type: OTHER; Interventions: Behavioral: Comparison group, Drug: Bupropion | Intervention Type: BEHAVIORAL; Name: High intensity disease management; Assigned to Arm(s): High intensity disease management | Intervention Type: BEHAVIORAL; Name: Low intensity disease management; Assigned to Arm(s): Low intensity disease management | Intervention Type: BEHAVIORAL; Name: Comparison group; Assigned to Arm(s): Comparison group | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Comparison group, High intensity disease management, Low intensity disease management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Brief Summary: This is a clinical trial which will evaluate the efficacy of Liprotamase treatment in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (PI).


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Creon N, then Creon®; Type: EXPERIMENTAL; Interventions: Drug: Creon® | Arm Label: Creon® , then Creon N; Type: EXPERIMENTAL; Interventions: Drug: Creon N | Intervention Type: DRUG; Name: Creon®; Assigned to Arm(s): Creon N, then Creon® | Intervention Type: DRUG; Name: Creon N; Assigned to Arm(s): Creon® , then Creon N
C: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
D: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Enteral Iron Supplementation on Anemia and Risk of Infection in Critical Illness
Brief Summary: The purpose of this study is to investigate the efficacy of enteral iron supplementation for improving anemia, decreasing the risk of blood transfusion, and decreasing mortality in patients who are hospitalized in the intensive care unit. This study will also address any relationship between enteral iron supplementation and risk of infection.


Options:
A: Arm Label: Ferumoxytol; Type: EXPERIMENTAL; Interventions: Drug: Ferumoxytol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Ferumoxytol; Assigned to Arm(s): Ferumoxytol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ferric Carboxymaltose (FCM); Type: EXPERIMENTAL; Interventions: Drug: Ferric Carboxymaltose (FCM) | Arm Label: Ferrous Sulfate tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ferrous Sulfate tablets | Intervention Type: DRUG; Name: Ferric Carboxymaltose (FCM); Assigned to Arm(s): Ferric Carboxymaltose (FCM) | Intervention Type: DRUG; Name: Ferrous Sulfate tablets; Assigned to Arm(s): Ferrous Sulfate tablets
C: Arm Label: Iron Group; Type: EXPERIMENTAL; Interventions: Drug: Ferrous Sulfate | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ferrous Sulfate; Assigned to Arm(s): Iron Group | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Group
D: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease Who Are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis
Brief Summary: The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and secondly to demonstrate the non-inferiority of efficacy between once weekly and once every two weeks dose schedules of Dynepo in patients previously stable on EPO, as measured by Hb over Weeks 16 to 24.


Options:
A: Arm Label: Epoetin Bio-Manguinhos; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa-BioManguinhos | Arm Label: EPO-BioSimilar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa-BioSimilar | Intervention Type: DRUG; Name: Epoetin Alfa-BioManguinhos; Assigned to Arm(s): Epoetin Bio-Manguinhos | Intervention Type: DRUG; Name: Epoetin Alfa-BioSimilar; Assigned to Arm(s): EPO-BioSimilar
B: Arm Label: CinnaPoietin®; Type: EXPERIMENTAL; Interventions: Drug: CinnaPoietin®, Drug: Nephrovit, Drug: Vitamin B12 Injection | Arm Label: Eprex®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eprex®, Drug: Nephrovit, Drug: Vitamin B12 Injection | Intervention Type: DRUG; Name: CinnaPoietin®; Assigned to Arm(s): CinnaPoietin® | Intervention Type: DRUG; Name: Eprex®; Assigned to Arm(s): Eprex® | Intervention Type: DRUG; Name: Nephrovit; Assigned to Arm(s): CinnaPoietin®, Eprex® | Intervention Type: DRUG; Name: Vitamin B12 Injection; Assigned to Arm(s): CinnaPoietin®, Eprex®
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo (Epoetin delta) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Intervention Type: DRUG; Name: Dynepo (Epoetin delta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Facilitating Informed Decisions for MSI Testing
Brief Summary: RATIONALE: The use of a CD-ROM may help patients with colorectal cancer or a family history of colorectal cancer make informed decisions about undergoing microsatellite instability (MSI) testing.

PURPOSE: This randomized clinical trial is studying an educational CD-ROM to see how well it works compared with standard informed consent to assist decision-making about MSI testing in patients with colorectal cancer or a family history of colorectal cancer.


Options:
A: Arm Label: Intervention Patients & Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PA | Arm Label: Intervention Patients, Control Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PA | Arm Label: Control Patients, Intervention Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Patients & Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-Randomized Controlled Trial Patients; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Providers; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Providers; Type: EXPERIMENTAL; Interventions: Behavioral: DECIDE-PC | Intervention Type: BEHAVIORAL; Name: DECIDE-PA; Assigned to Arm(s): Intervention Patients & Providers, Intervention Patients, Control Providers | Intervention Type: BEHAVIORAL; Name: DECIDE-PC; Assigned to Arm(s): Intervention Providers
B: Arm Label: Counseling; Type: NO_INTERVENTION; Interventions: Other: counseling intervention, Other: CD-ROM intervention | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Counseling | Intervention Type: OTHER; Name: CD-ROM intervention; Assigned to Arm(s): Counseling
C: Arm Label: communication skills training; Type: EXPERIMENTAL; Interventions: Behavioral: patient training in shared decision making | Arm Label: cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive training | Intervention Type: BEHAVIORAL; Name: patient training in shared decision making; Assigned to Arm(s): communication skills training | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): cognitive training
D: Arm Label: FRAX + Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX + Decision Aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FRAX estimated fracture risk; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX estimated fracture risk | Intervention Type: BEHAVIORAL; Name: FRAX + Decision Aid; Assigned to Arm(s): FRAX + Decision Aid | Intervention Type: BEHAVIORAL; Name: FRAX estimated fracture risk; Assigned to Arm(s): FRAX estimated fracture risk

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stepped Preventive Care to Reduce the Impact of Acute Pediatric Injury
Brief Summary: This study will evaluate the impact of a brief psychosocial intervention delivered to children or adolescents who are hospitalized for an unintentional injury. The intervention is designed to promote psychological recovery and enhance functional outcomes after injury. The study will also provide preliminary data concerning cost-effectiveness of the intervention.

The core study hypotheses are that children receiving the intervention will (1) have lower severity of post-traumatic stress disorder (PTSD) and depression symptoms at follow-up; (2) show greater adherence to discharge instructions and better health-related quality of life at follow-up, and (3) have higher rates of attendance at scheduled follow-up appointments and lower rates of emergency room utilization and re-hospitalization in the 6 months post-injury, compared to those receiving usual care.


Options:
A: Arm Label: Stepped Preventive Care; Type: EXPERIMENTAL; Interventions: Behavioral: stepped preventive care | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: stepped preventive care; Assigned to Arm(s): Stepped Preventive Care
B: Arm Label: KIDNET; Type: EXPERIMENTAL; Interventions: Behavioral: KIDNET | Arm Label: Meditation/Relaxation; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation-Relaxation | Intervention Type: BEHAVIORAL; Name: KIDNET; Assigned to Arm(s): KIDNET | Intervention Type: BEHAVIORAL; Name: Meditation-Relaxation; Assigned to Arm(s): Meditation/Relaxation
C: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy
D: Arm Label: Coping Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Coach | Arm Label: Coping Coach Waitlist Control; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Coach | Intervention Type: BEHAVIORAL; Name: Coping Coach; Assigned to Arm(s): Coping Coach, Coping Coach Waitlist Control

Answer: A